These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2313 related items for PubMed ID: 3556777

  • 41. The impact of MMR vaccine on mumps infection in England and Wales.
    Jones AG, White JM, Begg NT.
    CDR (Lond Engl Rev); 1991 Aug 16; 1(9):R93-6. PubMed ID: 1669792
    [Abstract] [Full Text] [Related]

  • 42. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children.
    Glikmann G, Petersen I, Mordhorst CH.
    Dan Med Bull; 1988 Apr 16; 35(2):185-7. PubMed ID: 3359817
    [Abstract] [Full Text] [Related]

  • 43. MMR vaccination and disease elimination: the Finnish experience.
    Davidkin I, Kontio M, Paunio M, Peltola H.
    Expert Rev Vaccines; 2010 Sep 16; 9(9):1045-53. PubMed ID: 20822347
    [Abstract] [Full Text] [Related]

  • 44. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.
    Weibel RE, Buynak EB, McLean AA, Hilleman MR.
    Pediatrics; 1975 Sep 16; 56(3):380-7. PubMed ID: 1161394
    [Abstract] [Full Text] [Related]

  • 45. Two doses of MMR vaccine--sufficient to eradicate measles, mumps and rubella?
    Fahlgren K.
    Scand J Soc Med; 1988 Sep 16; 16(3):129-35. PubMed ID: 3057621
    [Abstract] [Full Text] [Related]

  • 46. Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine.
    Topal B, Kanra G, Ceyhan M.
    Turk J Pediatr; 1991 Sep 16; 33(1):13-8. PubMed ID: 1844171
    [Abstract] [Full Text] [Related]

  • 47. The measles-mumps-rubella vaccination program in Finland.
    Redd SC, Wharton M, Hadler SC, Orenstein WA.
    N Engl J Med; 1995 Apr 20; 332(16):1102-3. PubMed ID: 7898540
    [No Abstract] [Full Text] [Related]

  • 48. [Knowledge of, attitudes toward and participation in the new vaccinations against measles, mumps and rubella during the first 2 years].
    Rønne T, Kaaber K, Petersen I.
    Ugeskr Laeger; 1989 Sep 18; 151(38):2418-22. PubMed ID: 2800014
    [Abstract] [Full Text] [Related]

  • 49. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
    André FE, Peetermans J.
    Dev Biol Stand; 1986 Sep 18; 65():101-7. PubMed ID: 3556770
    [Abstract] [Full Text] [Related]

  • 50. [Does a modified vaccination schedule protect better against measles?].
    van 't Spijker C, Rümke HC.
    Ned Tijdschr Geneeskd; 1994 Nov 26; 138(48):2400-5. PubMed ID: 7990988
    [Abstract] [Full Text] [Related]

  • 51. Measles vaccination: revised recommendations for immunization.
    Reece SM.
    Nurse Pract; 1990 Dec 26; 15(12):19-20, 23-4. PubMed ID: 2284058
    [Abstract] [Full Text] [Related]

  • 52. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age.
    Singh R, John TJ, Cherian T, Raghupathy P.
    Indian J Med Res; 1994 Oct 26; 100():155-9. PubMed ID: 7851964
    [Abstract] [Full Text] [Related]

  • 53. The timing of tuberculin tests in relation to immunization with live viral vaccines.
    Brickman HF, Beaudry PH, Marks MI.
    Pediatrics; 1975 Mar 26; 55(3):392-6. PubMed ID: 1143978
    [Abstract] [Full Text] [Related]

  • 54. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
    Just M, Berger R, Glück R, Wegmann A.
    Dev Biol Stand; 1986 Mar 26; 65():25-7. PubMed ID: 3549399
    [Abstract] [Full Text] [Related]

  • 55. When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa?
    Cameron NA.
    Vaccine; 2012 Sep 07; 30 Suppl 3():C58-60. PubMed ID: 22939023
    [Abstract] [Full Text] [Related]

  • 56. [Vaccine coverage and levels of protection with triple viral vaccine in a children population].
    Sánchez Serrano LP, Corcuera MT, Molina MP, de Miguel C, Lozano J, Oñorbe JA, Barberá G.
    Enferm Infecc Microbiol Clin; 1990 Sep 07; 8(6):384-7. PubMed ID: 2081176
    [Abstract] [Full Text] [Related]

  • 57. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M.
    Vaccine; 2014 Feb 26; 32(10):1147-52. PubMed ID: 24440207
    [Abstract] [Full Text] [Related]

  • 58. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L, Germann D, Bally F, Schopfer K.
    Eur J Epidemiol; 1997 Jan 26; 13(1):61-6. PubMed ID: 9062781
    [Abstract] [Full Text] [Related]

  • 59. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland.
    Paunio M, Virtanen M, Peltola H, Cantell K, Paunio P, Valle M, Karanko V, Heinonen OP.
    Am J Epidemiol; 1991 Jun 01; 133(11):1152-60. PubMed ID: 2035518
    [Abstract] [Full Text] [Related]

  • 60. Expanded programme on immunization. Immunization coverage against measles, mumps and rubella.
    Wkly Epidemiol Rec; 1993 Mar 19; 68(12):83-6. PubMed ID: 8452784
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 116.